Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Genes (Basel) ; 14(2)2023 02 03.
Article in English | MEDLINE | ID: mdl-36833328

ABSTRACT

The French mouse clinic (Institut Clinique de la Souris; ICS) has produced more than 2000 targeting vectors for 'à la carte' mutagenesis in C57BL/6N mice. Although most of the vectors were used successfully for homologous recombination in murine embryonic stem cells (ESCs), a few have failed to target a specific locus after several attempts. We show here that co-electroporation of a CRISPR plasmid with the same targeting construct as the one that failed previously allows the systematic achievement of positive clones. A careful validation of these clones is, however, necessary as a significant number of clones (but not all) show a concatemerization of the targeting plasmid at the locus. A detailed Southern blot analysis permitted characterization of the nature of these events as standard long-range 5' and 3' PCRs were not able to distinguish between correct and incorrect alleles. We show that a simple and inexpensive PCR performed prior to ESC amplification allows detection and elimination of those clones with concatemers. Finally, although we only tested murine ESCs, our results highlight the risk of mis-validation of any genetically modified cell line (such as established lines, induced pluripotent stem cells or those used for ex vivo gene therapy) that combines the use of CRISPR/Cas9 and a circular double-stranded donor. We strongly advise the CRISPR community to perform a Southern blot with internal probes when using CRISPR to enhance homologous recombination in any cell type, including fertilized oocytes.


Subject(s)
CRISPR-Cas Systems , Embryonic Stem Cells , Mice , Animals , Mice, Inbred C57BL , Embryonic Stem Cells/metabolism , Homologous Recombination , Mutagenesis
2.
Curr Protoc Mouse Biol ; 9(2): e62, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31145554

ABSTRACT

Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. While curative approaches for early stage HCC exist, effective treatment options for advanced HCC are lacking. Furthermore, there are no efficient chemopreventive strategies to limit HCC development once cirrhosis is established. One challenge for drug development is unsatisfactory animal models. In this article, we describe an orthotopic xenograft mouse model of human liver cancer cell lines through image-guided injection into the liver. This technique provides a less invasive yet highly efficient approach to engraft human HCC into mouse liver. Similarly, image-guided injections are used to deliver chemotherapeutics locally, enabling reduction in potential systemic adverse effects, while reducing the required dose for a therapeutic effect. In summary, this image-guided strategy provides a novel and convenient approach to improve current HCC mouse models. © 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.


Subject(s)
Heterografts/physiology , Liver Neoplasms, Experimental/therapy , Mice , Transplantation, Heterologous/methods , Ultrasonics/methods , Animals , Carcinoma, Hepatocellular/therapy , Liver Neoplasms/therapy , Transplantation, Heterologous/instrumentation , Ultrasonics/instrumentation
3.
Sci Rep ; 7(1): 13935, 2017 10 24.
Article in English | MEDLINE | ID: mdl-29066853

ABSTRACT

Hepatocellular carcinoma (HCC) is the only cancer for which non-invasive diagnosis is recognized by international guidelines. Contrast agent free ultrasound imaging, computed tomography (CT) and/or magnetic resonance imaging are techniques used for early detection and confirmation. Clinical evidence depicts that CT is 30% less precise as compared to MRI for detection of small tumors. In our work, we have reported some novel tools that can enhance the sensitivity and precision of CT applied to preclinical research (micro-CT). Our system, containing non-toxic nano-droplets loaded with iodine has high contrasting properties, liver and hepatocyte specificity and strong liver persistence. Micro-CT was performed on HCC model implanted in nude mice by intrahepatic injection. Contrast agent was administrated intravenously. This method allows an unprecedented high precision of detection, quantitative measurement of tumor volume and quantitative follow-up of the tumor development.


Subject(s)
Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/pathology , Halogenation , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Liver/diagnostic imaging , Nanotechnology , X-Ray Microtomography/methods , Animals , Cell Line, Tumor , Cell Proliferation , Cell Transformation, Neoplastic , Emulsions , Female , Humans , Liver/pathology , Mice , Ultrasonography
4.
Neuron ; 93(2): 331-347, 2017 Jan 18.
Article in English | MEDLINE | ID: mdl-28065649

ABSTRACT

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by a limited expansion of CGG repeats in the 5' UTR of FMR1. Two mechanisms are proposed to cause FXTAS: RNA gain-of-function, where CGG RNA sequesters specific proteins, and translation of CGG repeats into a polyglycine-containing protein, FMRpolyG. Here we developed transgenic mice expressing CGG repeat RNA with or without FMRpolyG. Expression of FMRpolyG is pathogenic, while the sole expression of CGG RNA is not. FMRpolyG interacts with the nuclear lamina protein LAP2ß and disorganizes the nuclear lamina architecture in neurons differentiated from FXTAS iPS cells. Finally, expression of LAP2ß rescues neuronal death induced by FMRpolyG. Overall, these results suggest that translation of expanded CGG repeats into FMRpolyG alters nuclear lamina architecture and drives pathogenesis in FXTAS.


Subject(s)
Ataxia/genetics , DNA-Binding Proteins/metabolism , Fragile X Mental Retardation Protein/genetics , Fragile X Syndrome/genetics , Membrane Proteins/metabolism , Nuclear Lamina/metabolism , Peptides/genetics , Protein Biosynthesis , RNA, Messenger/metabolism , Tremor/genetics , Trinucleotide Repeat Expansion/genetics , Animals , Ataxia/metabolism , Brain/metabolism , Brain/pathology , Fragile X Mental Retardation Protein/metabolism , Fragile X Syndrome/metabolism , Humans , Male , Mice , Mice, Transgenic , Nuclear Lamina/pathology , Peptides/metabolism , Real-Time Polymerase Chain Reaction , Tremor/metabolism
5.
BMC Cell Biol ; 17(1): 30, 2016 08 05.
Article in English | MEDLINE | ID: mdl-27496052

ABSTRACT

BACKGROUND: Karyotypic integrity is essential for the successful germline transmission of alleles mutated in embryonic stem (ES) cells. Classical methods for the identification of aneuploidy involve cytological analyses that are both time consuming and require rare expertise to identify mouse chromosomes. RESULTS: As part of the International Mouse Phenotyping Consortium, we gathered data from over 1,500 ES cell clones and found that the germline transmission (GLT) efficiency of clones is compromised when over 50 % of cells harbour chromosome number abnormalities. In JM8 cells, chromosomes 1, 8, 11 or Y displayed copy number variation most frequently, whilst the remainder generally remain unchanged. We developed protocols employing droplet digital polymerase chain reaction (ddPCR) to accurately quantify the copy number of these four chromosomes, allowing efficient triage of ES clones prior to microinjection. We verified that assessments of aneuploidy, and thus decisions regarding the suitability of clones for microinjection, were concordant between classical cytological and ddPCR-based methods. Finally, we improved the method to include assay multiplexing so that two unstable chromosomes are counted simultaneously (and independently) in one reaction, to enhance throughput and further reduce the cost. CONCLUSION: We validated a PCR-based method as an alternative to classical karyotype analysis. This technique enables laboratories that are non-specialist, or work with large numbers of clones, to precisely screen ES cells for the most common aneuploidies prior to microinjection to ensure the highest level of germline transmission potential. The application of this method allows early exclusion of aneuploid ES cell clones in the ES cell to mouse conversion process, thus improving the chances of obtaining germline transmission and reducing the number of animals used in failed microinjection attempts. This method can be applied to any other experiments that require accurate analysis of the genome for copy number variation (CNV).


Subject(s)
Aneuploidy , Karyotyping/methods , Metaphase , Mouse Embryonic Stem Cells/cytology , Mouse Embryonic Stem Cells/metabolism , Polymerase Chain Reaction/methods , Animals , Cells, Cultured , Chromosomes, Mammalian/metabolism , DNA Copy Number Variations , Germ Cells , Mice , Mice, Inbred C57BL
6.
PLoS Genet ; 12(3): e1005898, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26938916

ABSTRACT

BAHD1 is a vertebrate protein that promotes heterochromatin formation and gene repression in association with several epigenetic regulators. However, its physiological roles remain unknown. Here, we demonstrate that ablation of the Bahd1 gene results in hypocholesterolemia, hypoglycemia and decreased body fat in mice. It also causes placental growth restriction with a drop of trophoblast glycogen cells, a reduction of fetal weight and a high neonatal mortality rate. By intersecting transcriptome data from murine Bahd1 knockout (KO) placentas at stages E16.5 and E18.5 of gestation, Bahd1-KO embryonic fibroblasts, and human cells stably expressing BAHD1, we also show that changes in BAHD1 levels alter expression of steroid/lipid metabolism genes. Biochemical analysis of the BAHD1-associated multiprotein complex identifies MIER proteins as novel partners of BAHD1 and suggests that BAHD1-MIER interaction forms a hub for histone deacetylases and methyltransferases, chromatin readers and transcription factors. We further show that overexpression of BAHD1 leads to an increase of MIER1 enrichment on the inactive X chromosome (Xi). In addition, BAHD1 and MIER1/3 repress expression of the steroid hormone receptor genes ESR1 and PGR, both playing important roles in placental development and energy metabolism. Moreover, modulation of BAHD1 expression in HEK293 cells triggers epigenetic changes at the ESR1 locus. Together, these results identify BAHD1 as a core component of a chromatin-repressive complex regulating placental morphogenesis and body fat storage and suggest that its dysfunction may contribute to several human diseases.


Subject(s)
Chromosomal Proteins, Non-Histone/genetics , Nuclear Proteins/genetics , Placentation/genetics , Steroids/metabolism , Transcription Factors/genetics , Animals , Chromatin/genetics , Chromosomal Proteins, Non-Histone/biosynthesis , DNA-Binding Proteins , Estrogen Receptor alpha/genetics , Female , Gene Expression Regulation, Developmental , HEK293 Cells , Humans , Mice , Mice, Knockout , Nuclear Proteins/biosynthesis , Placenta/metabolism , Pregnancy , Transcription Factors/biosynthesis , Transcriptome/genetics
7.
Dis Model Mech ; 6(3): 608-21, 2013 May.
Article in English | MEDLINE | ID: mdl-23136396

ABSTRACT

Friedreich's ataxia (FRDA) is a recessive neurodegenerative disorder commonly associated with hypertrophic cardiomyopathy. FRDA is due to expanded GAA repeats within the first intron of the gene encoding frataxin, a conserved mitochondrial protein involved in iron-sulphur cluster biosynthesis. This mutation leads to partial gene silencing and substantial reduction of the frataxin level. To overcome limitations of current cellular models of FRDA, we derived induced pluripotent stem cells (iPSCs) from two FRDA patients and successfully differentiated them into neurons and cardiomyocytes, two affected cell types in FRDA. All FRDA iPSC lines displayed expanded GAA alleles prone to high instability and decreased levels of frataxin, but no biochemical phenotype was observed. Interestingly, both FRDA iPSC-derived neurons and cardiomyocytes exhibited signs of impaired mitochondrial function, with decreased mitochondrial membrane potential and progressive mitochondrial degeneration, respectively. Our data show for the first time that FRDA iPSCs and their neuronal and cardiac derivatives represent promising models for the study of mitochondrial damage and GAA expansion instability in FRDA.


Subject(s)
Friedreich Ataxia/pathology , Induced Pluripotent Stem Cells/pathology , Mitochondria/pathology , Mitochondrial Diseases/pathology , Models, Biological , Myocytes, Cardiac/pathology , Neurons/pathology , Cell Differentiation , Cell Line , DNA Mismatch Repair/genetics , DNA Repair Enzymes/metabolism , Fibroblasts/pathology , Humans , Membrane Potential, Mitochondrial , Mitochondria/metabolism , Mitochondria/ultrastructure , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/ultrastructure , Neurons/metabolism , Neurons/ultrastructure , Phenotype , Trinucleotide Repeat Expansion/genetics
8.
PLoS One ; 6(1): e16199, 2011 Jan 26.
Article in English | MEDLINE | ID: mdl-21298097

ABSTRACT

BACKGROUND: Frataxin, the mitochondrial protein deficient in Friedreich ataxia, a rare autosomal recessive neurodegenerative disorder, is thought to be involved in multiple iron-dependent mitochondrial pathways. In particular, frataxin plays an important role in the formation of iron-sulfur (Fe-S) clusters biogenesis. METHODOLOGY/PRINCIPAL FINDINGS: We present data providing new insights into the interactions of mammalian frataxin with the Fe-S assembly complex by combining in vitro and in vivo approaches. Through immunoprecipitation experiments, we show that the main endogenous interactors of a recombinant mature human frataxin are ISCU, NFS1 and ISD11, the components of the core Fe-S assembly complex. Furthermore, using a heterologous expression system, we demonstrate that mammalian frataxin interacts with the preformed core complex, rather than with the individual components. The quaternary complex can be isolated in a stable form and has a molecular mass of ≈190 kDa. Finally, we demonstrate that the mature human FXN(81-210) form of frataxin is the essential functional form in vivo. CONCLUSIONS/SIGNIFICANCE: Our results suggest that the interaction of frataxin with the core ISCU/NFS1/ISD11 complex most likely defines the essential function of frataxin. Our results provide new elements important for further understanding the early steps of de novo Fe-S cluster biosynthesis.


Subject(s)
Cell Survival , Iron-Binding Proteins/physiology , Iron-Sulfur Proteins/metabolism , Multiprotein Complexes/metabolism , Carbon-Sulfur Lyases/metabolism , Humans , Iron-Regulatory Proteins/metabolism , Mitochondrial Proteins , Multiprotein Complexes/biosynthesis , Protein Binding , Frataxin
9.
Haematologica ; 95(10): 1651-9, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20494935

ABSTRACT

BACKGROUND: Ex vivo manufacture of red blood cells from stem cells is a potential means to ensure an adequate and safe supply of blood cell products. Advances in somatic cell reprogramming of human induced pluripotent stem cells have opened the door to generating specific cells for cell therapy. Human induced pluripotent stem cells represent a potentially unlimited source of stem cells for erythroid generation for transfusion medicine. DESIGN AND METHODS: We characterized the erythroid differentiation and maturation of human induced pluripotent stem cell lines obtained from human fetal (IMR90) and adult fibroblasts (FD-136) compared to those of a human embryonic stem cell line (H1). Our protocol comprises two steps: (i) differentiation of human induced pluripotent stem cells by formation of embryoid bodies with indispensable conditioning in the presence of cytokines and human plasma to obtain early erythroid commitment, and (ii) differentiation/maturation to the stage of cultured red blood cells in the presence of cytokines. The protocol dispenses with major constraints such as an obligatory passage through a hematopoietic progenitor, co-culture on a cellular stroma and use of proteins of animal origin. RESULTS: We report for the first time the complete differentiation of human induced pluripotent stem cells into definitive erythrocytes capable of maturation up to enucleated red blood cells containing fetal hemoglobin in a functional tetrameric form. CONCLUSIONS: Red blood cells generated from human induced pluripotent stem cells pave the way for future development of allogeneic transfusion products. This could be done by banking a very limited number of red cell phenotype combinations enabling the safe transfusion of a great number of immunized patients.


Subject(s)
Erythrocytes/cytology , Induced Pluripotent Stem Cells/cytology , Cell Culture Techniques/methods , Cell Differentiation , Cell Line , Cytokines/pharmacology , Erythrocyte Transfusion , Humans
10.
PLoS One ; 4(7): e6379, 2009 Jul 24.
Article in English | MEDLINE | ID: mdl-19629184

ABSTRACT

BACKGROUND: Friedreich ataxia (FRDA), the most common form of recessive ataxia, is due to reduced levels of frataxin, a highly conserved mitochondrial iron-chaperone involved in iron-sulfur cluster (ISC) biogenesis. Most patients are homozygous for a (GAA)(n) expansion within the first intron of the frataxin gene. A few patients, either with typical or atypical clinical presentation, are compound heterozygous for the GAA expansion and a micromutation. METHODOLOGY: We have developed a new strategy to generate murine cellular models for FRDA: cell lines carrying a frataxin conditional allele were used in combination with an EGFP-Cre recombinase to create murine cellular models depleted for endogenous frataxin and expressing missense-mutated human frataxin. We showed that complete absence of murine frataxin in fibroblasts inhibits cell division and leads to cell death. This lethal phenotype was rescued through transgenic expression of human wild type as well as mutant (hFXN(G130V) and hFXN(I154F)) frataxin. Interestingly, cells expressing the mutated frataxin presented a FRDA-like biochemical phenotype. Though both mutations affected mitochondrial ISC enzymes activities and mitochondria ultrastructure, the hFXN(I154F) mutant presented a more severe phenotype with affected cytosolic and nuclear ISC enzyme activities, mitochondrial iron accumulation and an increased sensitivity to oxidative stress. The differential phenotype correlates with disease severity observed in FRDA patients. CONCLUSIONS: These new cellular models, which are the first to spontaneously reproduce all the biochemical phenotypes associated with FRDA, are important tools to gain new insights into the in vivo consequences of pathological missense mutations as well as for large-scale pharmacological screening aimed at compensating frataxin deficiency.


Subject(s)
Friedreich Ataxia/genetics , Iron-Binding Proteins/genetics , Mutation, Missense , Animals , Heterozygote , Mice , Mice, Transgenic , Frataxin
11.
FEBS J ; 276(4): 1036-47, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19154341

ABSTRACT

Friedreich ataxia (FRDA) is a rare hereditary neurodegenerative disease characterized by progressive ataxia and cardiomyopathy. The cause of the disease is a defect in mitochondrial frataxin, an iron chaperone involved in the maturation of Fe-S cluster proteins. Several human diseases, including cardiomyopathies, have been found to result from deficiencies in the activity of specific proteases, which have important roles in protein turnover and in the removal of damaged or unneeded protein. In this study, using the muscle creatine kinase mouse heart model for FRDA, we show a clear progressive increase in protein levels of two important mitochondrial ATP-dependent proteases, Lon and ClpP, in the hearts of muscle creatine kinase mutants. These proteases have been shown to degrade unfolded and damaged proteins in the matrix of mitochondria. Their upregulation, which was triggered at a mid-stage of the disease through separate pathways, was accompanied by an increase in proteolytic activity. We also demonstrate a simultaneous and significant progressive loss of mitochondrial Fe-S proteins with no substantial change in their mRNA level. The correlative effect of Lon and ClpP upregulation on loss of mitochondrial Fe-S proteins during the progression of the disease may suggest that Fe-S proteins are potential targets of Lon and ClpP proteases in FRDA.


Subject(s)
Creatine Kinase, MM Form/physiology , Endopeptidase Clp/biosynthesis , Iron-Binding Proteins/physiology , Iron-Sulfur Proteins/metabolism , Mitochondrial Proteins/physiology , Protease La/biosynthesis , Adenosine Triphosphate/metabolism , Animals , Creatine Kinase, MM Form/genetics , Friedreich Ataxia/genetics , Friedreich Ataxia/metabolism , Iron-Binding Proteins/genetics , Mice , Mice, Transgenic , Mutation , Myocardium/enzymology , Up-Regulation , Frataxin
12.
Hum Mol Genet ; 16(22): 2651-8, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17597094

ABSTRACT

Friedreich ataxia, the most common recessive ataxia, is caused by the deficiency of the mitochondrial protein frataxin (Fxn), an iron chaperone involved in the assembly of Fe-S clusters (ISC). In yeast, mitochondria play a central role for all Fe-S proteins, independently of their subcellular localization. In mammalian cells, this central role of mitochondria remains controversial as an independent cytosolic ISC assembly machinery has been suggested. In the present work, we show that three extramitochondrial Fe-S proteins (xanthine oxido-reductase, glutamine phosphoribosylpyrophosphate amidotransferase and Nth1) are affected in Fxn-deleted mouse tissues. Furthermore, we show that Fxn is strictly localized to the mitochondria, excluding the presence of a cytosolic pool of Fxn in normal adult tissues. Together, these results demonstrate that in mammals, Fxn and mitochondria play a cardinal role in the maturation of extramitochondrial Fe-S proteins. The Fe-S scaffold protein IscU progressively decreases in Fxn-deleted tissues, further contributing to the impairment of Fe-S proteins. These results thus provide new cellular pathways that may contribute to molecular mechanisms of the disease.


Subject(s)
Friedreich Ataxia/genetics , Iron-Binding Proteins/physiology , Iron-Sulfur Proteins/metabolism , Iron/metabolism , Mitochondria/metabolism , Sulfur/metabolism , Animals , Cytosol/metabolism , Mice , Mice, Transgenic , Mutation , Frataxin
SELECTION OF CITATIONS
SEARCH DETAIL
...